Roth Capital Lifts Earnings Estimates for Moleculin Biotech

Moleculin Biotech, Inc. (NASDAQ:MBRX) – Analysts at Roth Capital lifted their Q1 2025 earnings per share (EPS) estimates for shares of Moleculin Biotech in a report issued on Monday, March 24th. Roth Capital analyst J. Aschoff now anticipates that the company will earn ($0.71) per share for the quarter, up from their previous estimate of ($1.26). The consensus estimate for Moleculin Biotech’s current full-year earnings is ($7.98) per share. Roth Capital also issued estimates for Moleculin Biotech’s Q2 2025 earnings at ($0.46) EPS, Q3 2025 earnings at ($0.46) EPS, Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($2.02) EPS, FY2026 earnings at ($1.80) EPS, FY2027 earnings at ($1.73) EPS, FY2028 earnings at ($1.66) EPS and FY2029 earnings at $1.69 EPS.

Several other analysts have also issued reports on MBRX. Maxim Group upgraded shares of Moleculin Biotech from a “hold” rating to a “buy” rating and set a $4.00 price target on the stock in a research report on Tuesday. HC Wainwright reiterated a “buy” rating and issued a $8.00 price target on shares of Moleculin Biotech in a research note on Monday. Finally, StockNews.com upgraded Moleculin Biotech to a “sell” rating in a research report on Wednesday.

Moleculin Biotech Price Performance

MBRX stock opened at $1.05 on Wednesday. Moleculin Biotech has a 12 month low of $0.40 and a 12 month high of $6.23. The company’s 50-day moving average price is $1.30 and its two-hundred day moving average price is $1.99.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.